Compare Stocks

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PEAR Pear Therapeutics		$0.00	$0.03 ▼ $6.74	$4.17M	0.45	7.75 million shs	N/A
PIII P3 Health Partners	$0.50	$0.93	$0.45 ▼ $5.56	$158.27M	1.04	373,338 shs	269,507 shs

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PEAR Pear Therapeutics	0.00%	0.00%	0.00%	0.00%	-99.32%
PIII P3 Health Partners	+0.18%	-15.85%	-48.88%	-58.60%	-58.60%

Now Open: Crypto emergency update (Ad)

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
PEAR Pear Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PIII P3 Health Partners	0.8608 of 5 stars	3.3	2.0	0.0	0.0	0.6	0.8	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
PEAR Pear Therapeutics	N/A	N/A	N/A	N/A
PIII P3 Health Partners	2.50	Moderate Buy	$4.75	848.10% Upside

Current Analyst Ratings

Latest PEAR and PIII Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/1/2024	PIII P3 Health Partners	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
4/1/2024	PIII P3 Health Partners	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
3/14/2024	PIII P3 Health Partners	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$9.00 ➝ $4.50

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
PEAR Pear Therapeutics	$12.69M	0.00	N/A	N/A	$0.22 per share	0.00
PIII P3 Health Partners	$1.27B	0.12	$0.10 per share	5.01	$0.45 per share	1.11

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
PEAR Pear Therapeutics	-$75.49M	-$0.22	N/A	N/A	N/A	-594.70%	-217.85%	-95.20%	N/A
PIII P3 Health Partners	-$57.77M	-$0.65	N/A	N/A	N/A	-4.56%	-120.85%	-6.54%	5/8/2024 (Estimated)

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
PEAR Pear Therapeutics	N/A	N/A	N/A	N/A	N/A
PIII P3 Health Partners	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
PEAR Pear Therapeutics	N/A	1.48	1.48
PIII P3 Health Partners	0.76	0.55	0.55

Ownership

Institutional Ownership

Company	Institutional Ownership
PEAR Pear Therapeutics	71.17%
PIII P3 Health Partners	7.75%

Insider Ownership

Company	Insider Ownership
PEAR Pear Therapeutics	30.70%
PIII P3 Health Partners	17.06%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
PEAR Pear Therapeutics	300	142.74 million	98.92 million	Not Optionable
PIII P3 Health Partners	400	315.90 million	262.01 million	Not Optionable

PEAR and PIII Headlines

Source	Headline
	CareRx (OTCMKTS:CHHHF) versus P3 Health Partners (NASDAQ:PIII) Financial Survey americanbankingnews.com - April 19 at 1:16 AM
	P3 Health Partners to Present at the 23rd Annual Needham Virtual Healthcare Conference businesswire.com - April 3 at 8:00 AM
	William Blair Analysts Reduce Earnings Estimates for P3 Health Partners Inc. (NASDAQ:PIII) marketbeat.com - April 3 at 6:00 AM
	Equities Analysts Set Expectations for P3 Health Partners Inc.'s Q1 2025 Earnings (NASDAQ:PIII) marketbeat.com - April 2 at 6:38 AM
	P3 Health Partners (NASDAQ:PIII) Earns Outperform Rating from William Blair marketbeat.com - April 1 at 5:26 PM
	P3 Health Partners (NASDAQ:PIII) Rating Lowered to Neutral at BTIG Research marketbeat.com - April 1 at 8:29 AM
	P3 Health Partners: Q4 Earnings Insights benzinga.com - March 28 at 7:59 PM
	P3 Health Partners Inc. Reports Revenue Growth and Affirms 2024 Guidance, Despite Net Loss finance.yahoo.com - March 28 at 7:59 PM
	P3 Health Partners Announces Fourth Quarter and Full Year 2023 Results businesswire.com - March 28 at 4:05 PM
	P3 Health to report Q4 and full year 2023 earnings on March 28 uk.investing.com - March 17 at 3:04 PM
	P3 Health Partners to Participate in the Jefferies Value Based Healthcare Summit businesswire.com - February 28 at 8:00 AM
	P3 Health Partners to Present at the TD Cowen 44th Annual Healthcare Conference businesswire.com - February 19 at 8:00 AM
	P3 Health Partners to Participate in The 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference finance.yahoo.com - January 30 at 12:51 PM
	P3 Health Partners Inc.'s (NASDAQ:PIII) Path To Profitability finance.yahoo.com - January 19 at 8:47 AM
	P3 Health Partners reaffirms 2023 guidance, sees 2024 revenue above estimates msn.com - January 10 at 6:58 AM
	Why Health Management Company P3 Health Partners Shares Are Up Today markets.businessinsider.com - January 10 at 6:58 AM
	P3 Health Partners Reaffirms 2023 Guidance, Sees 2024 Revenue Above View; Stock Up markets.businessinsider.com - January 9 at 10:43 PM
	P3 Health Partners Reaffirms Guidance for 2023 and Announces Guidance for 2024 finance.yahoo.com - January 9 at 10:43 PM
	P3 Health Partners to Present at the 42nd Annual J.P. Morgan Healthcare Conference finance.yahoo.com - January 2 at 5:49 PM
	BTIG Research initates P3 Health Partners Inc (PIII) rating to a Buy knoxdaily.com - January 1 at 8:03 PM
	P3 Health Partners Inc Class A PIII morningstar.com - December 17 at 1:39 AM
	Positive Revenue Prospects and Improved Cash Flow: Reasons Behind David Larsen’s Buy Rating for P3 Health Partners markets.businessinsider.com - November 15 at 12:04 AM
	P3 Health Partners Inc. (NASDAQ:PIII) Q3 2023 Earnings Call Transcript finance.yahoo.com - November 12 at 1:24 PM
	P3 Health Partners Inc [PIII] Records 50-Day SMA of $1.7013 knoxdaily.com - November 10 at 8:42 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Pear Therapeutics

NASDAQ:PEAR

Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.

P3 Health Partners

NASDAQ:PIII

P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial